Myriad Genetics
  • Patients
    • I need help with…
      • Understanding hereditary cancer riskWhat is my risk of developing hereditary cancer?
      • Treating cancerWhat are my treatment options?
      • Guiding prenatal careAm I having a boy or girl?
        • Is my baby at risk for a genetic condition?
      • Managing mental healthHow might my genes affect my medication outcomes?
    • (sidebar parent)
      • About genetic testing
        • Affordability
        • Financial assistance
      • Patient Resources
        • How does genetic testing work?
        • Patient record request
        • Documents & forms
        • Blood draw locator
        • Blog
      • Prostate Cancer
        • What are my treatment options?
  • Providers
    • My patient needs a test for…
      • Assessing hereditary cancer riskWhat is my patient’s risk of developing hereditary cancer?
      • Cancer treatmentWhat is the best treatment for my patient?
      • Prenatal careWhat is the predicted fetal sex of my patient’s baby?
        • What is a pregnancy’s risk of a genetic disease?
      • Mental health treatmentHow will my patient metabolize or respond to certain medications?
    • (sidebar parent)
      • About our tests
        • Myriad test catalog
        • Scientific Publications
        • MyRisk® gene table
        • Affordability
        • Financial assistance
        • EMR Integrations
      • Provider resources
        • Order a test kit
        • Order patient materials
        • Documents & forms
        • Scope of service & lab certificates
        • Provider portal
        • Blood draw locator
        • Blog
      • Prostate Cancer Treatment
        • What are my patient’s treatment options?
  • Biopharma
  • Our Tests
    • Tests for…
      • (column wrapper)
        • Prenatal care
          • Fetal sex
          • Chromosome conditions
          • Genetic diseases
        • Cancer risk assessment
          • Hereditary cancer
        • Mental health
          • Depression
          • Anxiety
          • ADHD
      • (column wrapper)
        • Cancer management
          • Breast cancer
          • Ovarian cancer
          • Pancreatic cancer
          • Prostate cancer
          • Endometrial cancer
          • Other cancers
          • All tests
    • (sidebar parent)
      • TESTS BY SPECIALTY
        • Oncology
        • Urology
        • Imaging
        • OB/GYN
        • Mental Health
        • Internal/Primary care
        • All tests
      • TESTS BY NAME
        • BRACAnalysis CDx®
        • EndoPredict®
        • FirstGene™
        • Foresight®
        • GeneSight®
        • MyChoice® CDx
        • MyRisk® (cancer treatment)
        • MyRisk® (cancer risk)
        • Prequel®
        • Precise Tumor®
        • Prolaris®
        • SneakPeek®
  • About
    • About
      • (column wrapper)
        • About Myriad
        • Leadership
        • Investor relations
      • (column wrapper)
        • Newsroom
        • Careers
        • Contact
    • (sidebar parent)
      • Myriad Genetics Laboratory and Support Center
        • 322 North 2200 West
        • Salt Lake City, UT 84116
        • Corporate Phone: (801) 584-3600
        • Corporate Fax: (801) 584-3640
PORTALS ORDER
    Portals
    Order
  • Patients
    • I need help with…
      • Understanding hereditary cancer riskWhat is my risk of developing hereditary cancer?
      • Treating cancerWhat are my treatment options?
      • Guiding prenatal careAm I having a boy or girl?
        • Is my baby at risk for a genetic condition?
      • Managing mental healthHow might my genes affect my medication outcomes?
    • (sidebar parent)
      • About genetic testing
        • Affordability
        • Financial assistance
      • Patient Resources
        • How does genetic testing work?
        • Patient record request
        • Documents & forms
        • Blood draw locator
        • Blog
      • Prostate Cancer
        • What are my treatment options?
  • Providers
    • My patient needs a test for…
      • Assessing hereditary cancer riskWhat is my patient’s risk of developing hereditary cancer?
      • Cancer treatmentWhat is the best treatment for my patient?
      • Prenatal careWhat is the predicted fetal sex of my patient’s baby?
        • What is a pregnancy’s risk of a genetic disease?
      • Mental health treatmentHow will my patient metabolize or respond to certain medications?
    • (sidebar parent)
      • About our tests
        • Myriad test catalog
        • Scientific Publications
        • MyRisk® gene table
        • Affordability
        • Financial assistance
        • EMR Integrations
      • Provider resources
        • Order a test kit
        • Order patient materials
        • Documents & forms
        • Scope of service & lab certificates
        • Provider portal
        • Blood draw locator
        • Blog
      • Prostate Cancer Treatment
        • What are my patient’s treatment options?
  • Biopharma
  • Our Tests
    • Tests for…
      • (column wrapper)
        • Prenatal care
          • Fetal sex
          • Chromosome conditions
          • Genetic diseases
        • Cancer risk assessment
          • Hereditary cancer
        • Mental health
          • Depression
          • Anxiety
          • ADHD
      • (column wrapper)
        • Cancer management
          • Breast cancer
          • Ovarian cancer
          • Pancreatic cancer
          • Prostate cancer
          • Endometrial cancer
          • Other cancers
          • All tests
    • (sidebar parent)
      • TESTS BY SPECIALTY
        • Oncology
        • Urology
        • Imaging
        • OB/GYN
        • Mental Health
        • Internal/Primary care
        • All tests
      • TESTS BY NAME
        • BRACAnalysis CDx®
        • EndoPredict®
        • FirstGene™
        • Foresight®
        • GeneSight®
        • MyChoice® CDx
        • MyRisk® (cancer treatment)
        • MyRisk® (cancer risk)
        • Prequel®
        • Precise Tumor®
        • Prolaris®
        • SneakPeek®
  • About
    • About
      • (column wrapper)
        • About Myriad
        • Leadership
        • Investor relations
      • (column wrapper)
        • Newsroom
        • Careers
        • Contact
    • (sidebar parent)
      • Myriad Genetics Laboratory and Support Center
        • 322 North 2200 West
        • Salt Lake City, UT 84116
        • Corporate Phone: (801) 584-3600
        • Corporate Fax: (801) 584-3640

Category: Provider Blog

Urology > Provider Blog
  • Category
    • All
    • Patient Blog
    • Patient-Featured
    • Patients
    • Physician Blog
    • Prostate Cancer
    • Provider Blog
    • Providers
    • Urology
    • Video

This biomarker test is defining shared decision-making in celebration of Prostate Cancer Awareness Month

September 15, 2023

While androgen deprivation therapy (ADT) is effective at slowing the progression of prostate cancer by suppressing androgen production, it is often associated ...

Continue Reading

Exploring the Components and Utility of a Full Workup for Newly Diagnosed Prostate Cancer Patients

July 28, 2023

https://myriad-1.wistia.com/medias/z6zrgjhd4m We gathered a distinguished panel of experts, including Dr. Neal Shore, Dr. Ben Lowentritt, Dr. Ted Schaefer...

Continue Reading

Uncovering Genetic Abnormalities: A Prostate Cancer Patient’s Journey to Personalized Treatment

June 27, 2023

https://myriad-1.wistia.com/medias/1x6w5p6mip In the field of Urology, every patient's journey is unique, and sometimes, the unexpected can unfold. Kara C...

Continue Reading
A prostate cancer patient and his supportive son

Detecting more prostate cancer earlier with PSMA PET Scans

May 24, 2023

Prostate cancer doesn't always require aggressive treatment. Most men can delay complex treatment until necessary through Active Surveillance according to a ne...

Continue Reading

Healthcare Hero: Kara Cossis, Chesapeake Urology

April 12, 2023

At Myriad Genetics, our mission is to advance health and well-being for all, and a big component of that is developing reliable, accessible genetic tests for a...

Continue Reading

Medical Experts Discuss Benefits of Genetic Testing in Prostate Cancer Care

March 23, 2023

In a recent Myriad Live webinar, our Chief Medical Officer, Thomas Slavin, hosted a lively conversation about prostate cancer with two experts from the field: ...

Continue Reading

Expanding access to PARP inhibitors in prostate cancer treatment

March 14, 2023

Last month, Myriad attended the 2023 ASCO Genitourinary Cancers Symposium (ASCO GU) to connect with researchers and doctors around emergent and controversial a...

Continue Reading

Consistent data matters. Prolaris® is the best answer for your prostate cancer patients. Submit the form below to learn why.

August 26, 2022

Treating prostate cancer can be hard, Prolaris makes it easy Knowing if your prostate cancer patients are safe for active surveillance or if they would bene...

Continue Reading

Myriad Genetics is committed to being your partner of choice

August 5, 2022

Against the backdrop of recent shifts in the genetic testing industry, we would like to take a minute to reiterate Myriad Genetics’ determination to bring cl...

Continue Reading

Genetic insights for more actionable and personalized prostate cancer

March 25, 2022

Connect with us The AUA National meeting is centered around the exploration of the latest and groundbreaking advancements in urology, and th...

Continue Reading

Prolaris® is advancing prostate cancer care at ASCO GU

February 11, 2022

Prolaris now has 2 validated thresholds to make treatment decisions easier Prolaris is a prognostic, tumor-based biomarker test that measures the aggressive...

Continue Reading

Prolaris® is Helping Urologists Reimagine Prostate Cancer Care

November 2, 2021

This year’s LUGPA theme centers on re-imagining the practice of Urology. What better time than now to discover how incorporating genetic testing into your pr...

Continue Reading

New Study Proves that Prolaris can Determine which Patients Can Safely Avoid ADT

October 15, 2021

Historically, Urologists in practice have given Radiation Therapy (RT) or Androgen Deprivation Therapy (ADT) after initial prostate cancer treatment to red...

Continue Reading

New Data Validating the Prolaris® Test to Guide Treatment for Prostate Cancer

February 17, 2021

Myriad Genetics announces new data validating the prognostic power of the Prolaris multi-modal threshold and its ability to help predict which men with agg...

Continue Reading

1 in 6 Men with Prostate Cancer May Have a Hereditary, Disease-Causing Mutation

September 17, 2020

Knowing the status of your patient’s BRCA 1/2 germline status is critical. Myriad hereditary cancer tests give you definitive and actionable risk stratificat...

Continue Reading
  • 1
  • 2
  • Managed care
    • Payers
  • Investors
    • Investor relations
  • News
    • Newsroom
    • Blog
  • About
    • About Myriad
    • Careers
    • Contact us
  • Terms of Use
  • HIPAA Notice of Privacy Practices
  • Provider Portal Terms of Use
  • Privacy Notice
  • Patents
  • Health Privacy Notice
  • Compliance and Code of Conduct
  • Notice of Nondiscrimination and Discrimination Grievance Procedure
  • IT Security
  • Notice of Access to Language Assistance Services
  • Cookie Preferences
facebook linkedin x X/Twitter social network instagram youtube
  • © 2025 Myriad Genetics, Inc.

Locations

United States
Europe
Japan